Showing results (1-10 of 436) with videos related to
Sort By:
Pageof 44
Expert Opinion on Therapeutic Targets|April 16, 2008
Novel therapeutic targets in the treatment of IBDArthur Kaser, Herbert TilgExpert Opinion on Biological Therapy|October 22, 2002
Antitumour necrosis factor therapy in Crohn's diseaseHerbert Tilg, Arthur KaserExpert Opinion on Biological Therapy|April 23, 2004
Type I interferons and their therapeutic role in Th2-regulated inflammatory disordersHerbert Tilg, Arthur KaserThe Journal of Clinical Investigation|June 3, 2011
Gut microbiome, obesity, and metabolic dysfunctionHerbert Tilg, Arthur KaserCurrent Drug Delivery|October 26, 2011
"Metabolic aspects" in inflammatory bowel diseasesArthur Kaser, Herbert TilgCurrent Opinion in Investigational Drugs (London, England : 2000)|December 16, 2010
Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's diseaseHerbert Tilg, Arthur KaserExpert Opinion on Therapeutic Targets|February 25, 2009
Inflammatory bowel diseases: highlights from the United European Gastroenterology Week 2008Arthur Kaser, Herbert TilgNature Clinical Practice. Gastroenterology & Hepatology|November 3, 2005
Treatment strategies in nonalcoholic fatty liver diseaseHerbert Tilg, Arthur KaserExpert Opinion on Biological Therapy|August 2, 2007
Mode of function of biological anti-TNF agents in the treatment of inflammatory bowel diseasesHerbert Tilg, Alexander Moschen, Arthur KaserEuropean Cytokine Network|March 26, 2009
Suppression of interleukin-17 by type I interferons: a contributing factor in virus-induced immunosuppression?Herbert Tilg, Alexander R Moschen, Arthur KaserPageof 44